N/A N=20 Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack
Transient Ischemic Attack
Primary: Functional Walk Test — 498.4; 503.2; 564.2 meters — p==0.06
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
Phase 3 N=11,016 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
Phase 2 N=50 TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
Ischemic Stroke
Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
Phase 3 N=13,199 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Number of Participants With Composite of Stroke/MI/Death — 442; 497 Participants — p=0.0670
N/A N=1,135 Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
Transient Ischemic Attack · Stroke
Primary: Effectiveness: Without-fail Care Rate — 95; 363 Participants
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Phase 2 N=15 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Thrombosis
Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28
N/A N=36 Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.
Ischemic Stroke · Thrombotic Stroke · Autonomic Dysfunction
Primary: Blood Pressure Variability — 0.106; 0.107 coefficient of variation
N/A N=140 Reducing Risk of Recurrence
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=1,560 Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
N/A N=11 Intracardiac T-wave Alternans and Ischemia
Ischemia
Primary: Number of Subjects With Positive T Wave Studies During a Coronary Intervention — 0 participants
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
Phase 2 N=53 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
N/A N=1,655 SITS-IVT in Patients >80 Years Study
Ischaemic Stroke
Primary: Number of Participants With Symptomatic Intracerebral Haemorrhage (SICH) Per Safe Implementation of Thrombolysis - Stroke-Monitoring Study (SITS-MOST) Definition — 14…
Phase 3 N=204 A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
Stroke, Acute · Neurological Impairment
Primary: Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period. — 59.8; 64.7 percentage of participants — p=0.52
Phase 4 N=203 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…
Phase 2 N=103 The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
Cerebrovascular Disease
Primary: Blood Pressure and Heart Rates;
N/A N=252 Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
Transient Ischemic Attack · Stroke
Primary: HOMA IR Change From Baseline — 0.9; 4.0; 4.1 HOMA-IR Index
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
N/A N=55 The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
Carotid Artery Diseases · Carotid Atherosclerosis · Carotid Stenosis
Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants